S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma

Published:2013-08 Issue:12 Volume:49 Page:2643-2653
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bachet Jean-Baptiste,Maréchal Raphael,Demetter Pieter,Bonnetain Franck,Cros Jérôme,Svrcek Magali,Bardier-Dupas Armelle,Hammel Pascal,Sauvanet Alain,Louvet Christophe,Paye François,Vaillant Jean-Christophe,André Thierry,Closset Jean,Salmon Isabelle,Emile Jean-François,Van Laethem Jean-Luc

Funder

ARCAD (Aide et Recherche en Cancérologie Digestive) foundation

AROLD (Association pour la Recherche en OncoLogie Digestive) association

Fonds Erasme

DIAPATH-CMMI (European Regional Development Fund and the Walloon Region)

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry;Carpelan-Holmström;Gut,2005

2. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009